Biovitrum

Swedish Orphan Biovitrum (Sobi) is an integrated biopharmaceutical company headquartered in Stockholm, Sweden, with a strategic focus on developing and delivering treatments for rare diseases. The company has a long and complex history tracing back to the 1930s and has evolved through a series of mergers and acquisitions. Biovitrum was officially formed in 2001 when it was spun out of Pharmacia, combining several of its units, and was backed by investors including Nordic Capital and MPM Capital Funds. A pivotal moment occurred in 2010 when Biovitrum acquired Swedish Orphan International, a pioneer in orphan drugs, leading to the creation of the current entity, Swedish Orphan Biovitrum AB, or Sobi.

Sobi operates in the biopharmaceutical market, concentrating on therapeutic areas with high unmet medical needs, specifically haematology, immunology, and specialty care. The company serves a global patient population affected by rare conditions, providing access to its therapies in over 70 countries. Its business model is centered on a combination of in-house research and development, strategic partnerships, and acquisitions to build its product pipeline. Revenue is generated primarily from the sale of its specialized pharmaceutical products, which include treatments for haemophilia, immune thrombocytopenia (ITP), and various genetic and metabolic diseases. The company has demonstrated a consistent growth strategy, including the acquisition of Dova Pharmaceuticals in 2019 and CTI BioPharma in 2023, which significantly expanded its haematology franchise and presence in North America.

The company's product portfolio is extensive, featuring therapies developed through its expertise in protein biochemistry and biologics manufacturing. Key products include Elocta® and Alprolix® for haemophilia, Gamifant® for primary hemophagocytic lymphohistiocytosis (HLH), and Kineret® for several inflammatory conditions. Sobi also manufactures and markets products for partner companies, such as the active protein component for Pfizer's ReFacto®/Xyntha® drugs. The firm's commitment to patients is a core part of its strategy, focusing on late-stage research, patient access, and commercialization to address the needs of the rare disease community.

Keywords: biopharmaceutical, rare diseases, orphan drugs, haematology, immunology, specialty care, protein biochemistry, biologics manufacturing, haemophilia, genetic diseases, metabolic diseases, autoimmune diseases, inflammation, oncology supportive care, ReFacto, Elocta, Alprolix, Gamifant, Kineret, Doptelet, Sobi, Swedish Orphan Biovitrum, Stockholm, Nasdaq Stockholm: SOBI, pharmaceutical development